How Are Allergic Conjunctivitis Companies Going To Change The Market Landscape?

>

How are Allergic Conjunctivitis companies going to change the market landscape?

Allergic Conjunctivitis is a common eye condition in which the tissue that lines the inside of the eyelid and outside of the eyeball called conjunctiva becomes inflamed. It usually happens when a person's eyes come into contact with an allergen, a substance that makes the body's immune system to overreact. The disease can be acute or chronic. 

 

Allergic Conjunctivitis Epidemiology 

 

“Males are more affected by allergic conjunctivitis when compared with females.”

 

Among 7MM, the total diagnosed allergic conjunctivitis prevalent cases in 2017 were found out to be 65,502,156, out of which the highest diagnosed allergic conjunctivitis prevalent cases were seen in the United States, which is followed by EU5 and Japan. Among acute allergic conjunctivitis cases are found to be more prevalent as compared to the chronic cases. Among EU5 countries, Germany has the highest allergic conjunctivitis prevalent population, followed by Italy. Spain accounts for the lowest number of allergic Conjunctivitis in prevalent cases. The estimates show higher diagnosed allergic conjunctivitis prevalence in the United States with 33,805,769 diagnosed cases in 2017.

 

Allergic Conjunctivitis marketed drugs

 

There have been many drugs used in the past for Allergic Conjunctivitis treatment market like decongestants (Lotemax, Alrex), mast cell stabilizers (Alocril, Pataday), dual-action antihistamines (Patanol, Beprev), and many more. In the coming years, the competitive landscape for the Allergic Conjunctivitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. Also, a slew of biotechnological companies are developing many drugs. Some of the companies are mentioned below with their emerging drug profiles.

 

 

The key players and emerging therapies for Allergic Conjunctivitis market are:  

 

  •    Aldeyra Therapeutics, the United States based biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. 

 

Aldeyra Therapeutics is developing Reproxalap and is believed to be the most promising emerging therapy in the Allergic Conjunctivitis Market. It has been observed that Reproxalap's novel aldehyde trapping mechanism produces clinically relevant effects comparable to existing therapies along with safety profiles. The drug overcomes the severe side effects caused by steroids. Thus, this drug is considered to be a great relief for the patients suffering from the disease.  

 

Reproxalap accounts for a new mechanism for decreasing ocular inflammation in Allergic Conjunctivitis. Reproxalap may have a more beneficial therapeutic profile than presently approved drugs for each indication, having shown the potential for new durable business in Allergic Conjunctivitis. Moreover, reproxalap, it got approved, also has the added possibility of being the only drug that may treat Allergic Conjunctivitis effectively.

 

  •    Ocular Therapeutix,Inc., Massachusetts based biopharmaceutical company aimed to develop, manufacture and market novel therapies for the eye diseases using its proprietary hydrogel-based formulation technology.

 

 

 

 

 

  •    Portola Pharmaceuticalsis a California based clinical-stage biotechnology company that focusses on research, development and commercialization drugs. The company aims primarily on drugs used in the treatment of thrombosis and haematological malignancies.

 

Portola Pharmaceuticals has collaborated with Ora, Inc. for the development of PRT2761, Portola's highly selective Syk inhibitor, in ophthalmic diseases. The Syk inhibition may completely stop the activation of mast cells in ocular allergy and, hence, a Syk inhibitor could become a potential therapeutic option.

 

  • Bilastine is a second-generation antihistamine drug developed by FAES Farma. FAES FARMA, a Spanish pharmaceutical company with an aim to research, production and market pharmaceutical products and raw materials, which are exported to many countries.

 The drug developed is in Phase III stage for Allergic Conjunctivitis and is already an approved therapy for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU) (such as itchiness and hives).

 

The dynamics of Allergic Conjunctivitis market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2018-2027.  An increase in the awareness about allergic conjunctivitis among patients, medical communities, and people associated with this disease is one of the major drivers for the growth of global allergic conjunctivitis market.

 

 

 

 

 

 

Share:

Keywords: allergic conjunctivitis,allergic conjunctivitis market,allergic conjunctivitis market share,allergic conjunctivitis market size,eye disease

Comments

Other related blogs

Succeed Your WoW Classic With These Verified Ideas

By : Lootwowgold

Boost how well you are doing at specific sports, playing online games can assist you, in order to in..


How Long Does It Take to Process Plastic Molds

By : Petblowingmachine

How long does it take to process plastic molds? This problem cannot be generalized. From the perspec..


Choose the Best Facilities Planning Consultant in India today

By : Seospidy

Food Service Design India is most reputed Facilities Planning Consultant in India that offers premiu..


Contact hp technical support Issues and Solutions

By : Contact US - Help

HP help desk is known for products such as or HP printers help desk number, Hp laptops, Hp Desktop, ..